Optimal control applied to cell-cycle-specific cancer chemotherapy

SIAM Journal on Applied Mathematics

Volumn 60, Issue 3, 2000, Pages 1059-1072

  Fister, K Renee ^a   Panetta, John Carl ^b  

^a MURRAY STATE UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; CELLS; CHEMOTHERAPY; DOSIMETRY; ONCOLOGY; OPTIMAL CONTROL SYSTEMS;

BONE MARROW; CELL CYCLE;

MATHEMATICAL MODELS;

EID: 0033687699     PISSN: 00361399     EISSN: None     Source Type: Journal    
DOI: 10.1137/s0036139998338509     Document Type: Article

References (22)

1. Z. AGUR, The effect of drug schedule on responsiveness to chemotherapy, Ann. New York Acad. Sci., 504 (1986), pp. 274-277.
2. Z. AGUR, R. ARNON, AND B. SCHECHTER, Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs, Math. Biosci., 92 (1988), pp. 1-15.
3. L. COJOCARU AND Z. AGUR, A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs, Math. Biosci., 109 (1992), pp. 85-97.
4. M. EISEN, Mathematical Models in Cell Biology and Cancer Chemotherapy, Lecture Notes in Biomath. 30, Springer-Verlag, New York, 1979.
5. W. H. FLEMING AND R. W. RISHEL, Deterministic and Stochastic Optimal Control, Springer-Verlag, New York, 1975.
6. J. D. HAINSWORTH AND F. A. GRECO, Paclitaxel administered by 1-hour infusion, Cancer, 74 (1994), pp. 1377-1382.
7. M. KAMIEN AND N. SCHWARTZ, Dynamic Optimization: The Calculus of Variations and Optimal Control in Economics and Management, North-Holland, Amsterdam, 1991.
8. J. LIEBMANN, J. COOK, C. LIPSCHULTZ, D. TEAGUE, J. FISHER, AND J. MITCHELL, Cytotoxic studies of paclitaxel (Taxol) in human cell lines, Br. J. Cancer, 68 (1993), pp. 1104-1109.
9. M. M. LOPES, E. G. ADAMS, T. W. PITTS, AND B. K. BHUYAN, Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines, Cancer Chemother. Pharmacol., 32 (1993), pp. 235-242.
10. D. L. LUKES, Differential Equations: Classical to Controlled, Math. Sci. Engrg. 162, Academic Press, New York, 1982.
11. M. C. MACKEY, Unified hypothesis for the origin of aplastic anemia and periodic hematopoiesis, Blood, 51 (1978), pp. 941-956.
12. J. M. MURRAY, Optimal control for a cancer chemotherapy problem with general growth and loss functions, Math. Biosci., 98 (1990), pp. 273-287.
13. J. M. MURRAY, Some optimal control problems in cancer chemotherapy with a toxicity limit, Math. Biosci., 100 (1990), pp. 49-67.
14. J. C. PANETTA, A mathematical model of breast and ovarian cancer treated with paclitaxel, Math. Biosci., 146 (1997), pp. 89-113.
15. J. C. PANETTA AND B. C. HIGGINS, A nonlinear mathematical model of breast and ovarian cancer treated with paclitaxel, J. Theoret. Biol., submitted.
16. H. L. ROYDEN, Real Analysis, 3rd ed., Macmillian Publishing, New York, 1988.
17. G. W. SWAN, Role of optimal control theory in cancer chemotherapy, Math. Biosci., 101 (1990), pp. 237-284.
18. A. SWIERNIAK, A. POLANSKI, AND M. KIMMEL, Optimal control problems arising in cell-cycle-specific cancer chemotherapy, Cell Prolif., 29 (1996), pp. 117-139.
19. W. W. TEN BOKKEL HUININK, E. EISENHAUER, AND K. SWENERTON, Preliminary evaluation of a multicenter randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Rev., 19 (1993), pp. 79-86.
20. G. F. WEBB, Resonance phenomena in cell population chemotherapy models, Rocky Mountain J. Math., 20 (1990), pp. 1195-1216.
21. G. F. WEBB, Resonances in periodic, chemotherapy scheduling, in Proceedings of First World Congress of Nonlinear Analysts, Vol. 4, V. Lakshmikantham, ed., Walter DeGruyter, Berlin, 1995, pp. 3463-3747.
22. W. H. WILSON, S. L. BERG, G. BRYANT, R. E. WITTES, S. BATES, A. FOJO, S. M. STEINBERG, B. R. GOLDSPIEL, J. HERDT, J. O'SHAUGHNESSY, F. M. BALIS, AND B. A. CHABNER, Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion, J. Clinical Oncology, 12 (1994), pp. 1621-1629.